Drug Delivery Business News, reported that San Diego-based Dexcom submitted a 15-day version of its G7 continuous glucose monitor (CGM) to the FDA. The technology previously had a wear time of 10 days. This would match it with the recently launched Stelo biosensor, which was developed on the G7 platform and has a 15-day wear time.

The company yesterday evening also reported third-quarter results that topped the consensus forecast. Shares of DXCM were up slightly at the opening of trading today.